BIOXCEL THERAPEUT
BIOXCEL THERAPEUT
Aktie · US09075P1057 · BTAI · A2JF20 (LSSI)
Übersicht Finanzkennzahlen
1,75 EUR
5,82 % 0,10 EUR
Lang & Schwarz (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
10.06.2025 23:45

Aktuelle Kurse von BIOXCEL THERAPEUT

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
BTAI
USD
10.06.2025 23:45
2,00 USD
1,96 USD
+2,04 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 28,44 % 30,13 % -39,38 % -73,87 % -91,84 % -99,76 %

Firmenprofil zu BIOXCEL THERAPEUT Aktie

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Unternehmensdaten

Name BIOXCEL THERAPEUT
Firma BioXcel Therapeutics, Inc.
Symbol BTAI
Website https://www.bioxceltherapeutics.com
Heimatbörse LSSI Lang & Schwarz
WKN A2JF20
ISIN US09075P1057
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Vimal D. Mehta Ph.D.
Land Vereinigte Staaten von Amerika
Währung EUR
Mitarbeiter 0,0 T
Adresse 555 Long Wharf Drive, 06511 New Haven
IPO Datum 2018-03-08

Aktien-Splits

Datum Split
10.02.2025 1:16

Ticker Symbole

Name Symbol
Frankfurt BX2.F
NASDAQ BTAI

Weitere Aktien

Investoren die BIOXCEL THERAPEUT die halten, haben auch folgende Aktien im Depot:
ACACIA RESEARCH CORP
ACACIA RESEARCH CORP Aktie
ADOBE INC
ADOBE INC Aktie
AMAZON.CO INC
AMAZON.CO INC Aktie
AMGEN INC
AMGEN INC Aktie
BARING GER.GR.TR.ACC.UTS
BARING GER.GR.TR.ACC.UTS Fonds
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
DZ BANK      IS.A1872
DZ BANK IS.A1872 Anleihe
INTEL CORP
INTEL CORP Aktie
NETFLIX INC
NETFLIX INC Aktie
NVIDIA CORP
NVIDIA CORP Aktie
PRISMAFLEX       EO 2
PRISMAFLEX EO 2 Aktie
TESLA INC
TESLA INC Aktie
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025